
|Podcasts|July 5, 2023
Achieving Durable Clinical Response with Targeted Treatments for Vitiligo
Listen
0:00 / 0:00
In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.
Advertisement
0:53 Quality of life impact of vitiligo
2:55 Pathogenesis of vitiligo
5:08 Approaches to vitiligo treatment
8:30 Mechanism of JAK inhibitors
10:25 TRuE-V1 and TRuE-V2 studies for the JAK inhibitor ruxolitinib
14:15 Variation in repigmentation with vitiligo
17:20 Safety of topical ruxolitinib
21:00 Data from the long-term extension trial of ruxolitinib
25:75 Achieving meaningful treatment response in vitiligo
30:15 Investigational biomarkers and treatments for vitiligo
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
New Topicals in Atopic Dermatitis: Evidence, Barriers, and Real-World Perspectives
2
Treatment Selection, Adherence, and Misconceptions in Pediatric Atopic Dermatitis
3
Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD
4
Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial
5











































































